I. Introduction
Clinical trials involving human subjects are a significant component of R&D expenditures in the US economy, with important implications for human health, physician practice and revenues, national and regional economic performance, and academic medicine. This raises some very basic-and as yet unanswered-questions. Increases in the cost per approved drug are often equated with "the price of innovation", but in fact little is known about how much of the increase in expenditure reflects changes in the prices of inputs to biomedical research and how much reflects changes in the quantity of research being performed.
Have the prices of inputs to clinical research increased more rapidly than overall inflation, or are these inputs being used more intensively, or are both occurring? Moreover, to what extent has the "quality" of inputs changed? The growing complexity of clinical trials and the underlying science suggests that more time, more highly trained personnel, and more sophisticated equipment may be required to conduct a typical study.
), the number of new drugs and biologics approved by the FDA each year in the last decade has, at best, been static, and considerably less than during the 1990s. One prominent study (DiMasi et.
al [2003] ) reports that the capitalized cost of bringing a new drug to market, adjusted for general inflation in year 2000 dollars, more than doubled from $318 to $802 million between 1991 and 2003. 5 Very little data is currently available to inform discussion of such issues. While data are captured for some inputs to clinical research, such as salaries of post-doctoral fellows, relatively little is known about other important inputs to clinical research such as site administration costs, computational time, materials and investigator salaries. Critically, even where good data are available on input prices, it is important to take into account how inputs are combined by focusing on an appropriate unit of analysis.
The highly influential studies by Cutler and coauthors on the costs of treating heart attacks have had a major impact on analyses of health expenditures by focusing attention on changes in the cost of an "episode of care" due to input substitution, rather than on changes in the per unit-price of inputs to care. 6 This observation may be particularly relevant in analyzing biomedical clinical research since this activity is widely believed to have become more costly not just because of increases in input costs, but because it has become more complex, more timeconsuming, and more resource-intensive. Any effort to understand the causes and consequences of rising expenditure on clinical research must take these changes into account. The importance of such detailed research has recently been emphasized by a Conference Board/NSF workshop, which concluded, inter alia, that in order to support a new micro-to-macro research data infrastructure, "…comprehensive data on innovation input costs could be collected according to concepts used in modern business organizations." 7 More generally, in the language of the economics of price measurement, we need to think about "constant-quality" changes in prices and quantities, i.e., hold the characteristics of the input and output activities constant when looking at changes in expenditures over time or crosssectionally. Failure to do so can result in quite misleading interpretations and policy recommendations. Analyses of expenditures on computers, for example, recognize that there have been huge increases in the performance or capacity of the products sold, but very small changes in their nominal prices; "constant quality" prices have thus fallen substantially over time-various estimates suggest sustained real price declines of more than 25% per year over several decades. 8 Various governmental statistical agencies now routinely take this phenomenon into account for many types of information technology and other electronic goods in developing estimates of GDP, with quite marked impacts on measures of economic growth and productivity. 9 While it is important, therefore, to quantify the "price" versus "quantity" component changes in R&D, adjusting both for quality, characterizing scientific research presents some very substantial measurement problems. Research activities are typically highly heterogeneous and idiosyncratic in nature, drawing on quite different inputs and resources to produce "output" which is very difficult to measure consistently. However in one respect, clinical trials may be unusually tractable. Clinical development is a highly structured activity, in which individual "experiments" are relatively well-defined and activity is closely tracked. Industry trends are also creating an unusual opportunity to investigate these questions. While biopharmaceutical companies and non-profit entities continue to be the lead sponsors of clinical trials, much of the effort in conducting them is increasingly outsourced to contract research organizations ("CROs")
rather than being incurred "in house". At least within the US, the investigators who recruit, treat, and observe subjects are drawn less from academic medical centers and increasingly more from independent physician practices. 10 The only existing R&D price index of which we are aware is the Biomedical Research This has meant that data on contractual terms among all these parties are now ever more important and increasingly visible.
"Theoretically, the annual change in the BRDPI indicates how much NIH expenditures would need to increase, without regard to efficiency gains or changes in government priorities, to compensate for the average increase in prices due to inflation and to maintain NIH-funded research activity at the previous year's level."
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The BRDPI is published annually on a federal government fiscal year (October 1 -September 30) basis.
In this manuscript we report results from analyses of a sample of over 215,000 contracts regarding payments made by trial sponsors (directly or through CRO intermediaries) to clinical investigators and study sites from the PICAS® database maintained by MediData Worldwide Solutions, Inc. This sample covers over 24,000 distinct Phase 1 through Phase 4 clinical study protocols conducted between 1989 and 2011 in 52 different countries. Using information on the protocol characteristics we compute hedonic price indexes that allow us to estimate the rate of inflation in this particular aspect of clinical research, controlling for changes in the characteristics of clinical trials over the sample period. We find that while our measure of unit costs of this aspect of conducting clinical trials rose rapidly over the two decades covered by this sample at 8% per year (roughly twice the rate of inflation in the NIH's Biomedical R&D Price Index), these changes in nominal costs appear to be driven by a variety of factors other than input costs. At least in this sample there has been a substantial increase in the level of effort required by investigators, and significant changes in both the composition of the sample across therapeutic classes and stages of clinical development, as well as in the organization of trials with a trend towards smaller numbers of patients per site and considerable variation over time in the geographic distribution of ex-US sites. After controlling for these factors using hedonic regression methods, we find much lower growth rates in costs, with adjusted rates of inflation between 1/3 and 2/3 lower than those seen in the unadjusted data.
II. Data
With the co-operation of MediData Worldwide Solutions, Inc. ("MediData") we assembled a dataset of more 216,076 observations on "investigator grants," which are payments made by a trial sponsor to the individual investigators or "sites" that enroll subjects.
12 Table I shows a summary of the number of records in the dataset by year each investigator contract was signed, along with summary statistics for the total grant cost per These contracts are excluded from the results reported below, since we are unable to control for the scale of the site's effort. For ex-US sites where the contract is in a foreign currency, we convert to US dollars using the spot exchange rate. Typically these payments make up about half of the total cost of a trial, the remainder being "overhead" in the form of data management, site selection and monitoring, etc. by the sponsors. The distribution of TGPP is quite skewed, with the median somewhat below the mean value; a visual plot suggests that TGPP can be reasonably approximated with the lognormal distribution. Notably, the within-year coefficient of variation is relatively large but stable at around 0.80 at both the beginning and end of the sample period. While we attempt to account for this variation in TGPP with measured site and protocol characteristics, some part is likely attributable to factors such as the conversion of foreign transactions to US $ using the spot exchange rate at the time of the transaction. 16 , or where unavailable or inapplicable, comparable Work Effort Unit (WEUs) created by MediData in conjunction with researchers at the Tufts Center for Study of Drug Development, were assigned to each procedure in a trial protocol. A complexity measure was computed simply as the number of distinct procedures in the trial protocol. An aggregate investigative SWE measure was then computed as the cumulated product of the number and intensity in use of these procedures, in RVU/WEU units, conducted over the course of the entire protocol for each of the trials. 17 It is important to note that SWE is therefore a protocol-level measure of the work effort required from each site, and that actual resources used by each site in implementing the protocol may differ to some degree. Reflecting the burden of disease, trials involving the six "largest" therapeutic areas (central nervous system, cardiovascular, respiratory system, endocrine, oncology and anti-infectives) make up 70% of the sample. Shares of central nervous system and oncology trials grew somewhat over time until 2005-6, while cardiovascular shrank, suggesting that to the extent central nervous system and oncology trials are relatively more costly to conduct, these compositional changes may have some effect on increases in average TGPP. Table V presents the geographic breakdown of the sites in this sample. Over the entire sample time period, 56% of sites were in the US, with most of the remainder in other OECD countries, and only 5.4% in the rest of the world. Interestingly, although the US share is about 80% in both the earliest and latest years, there is substantial year-to-year and trend variability.
As shown in Table I 
III. Hedonic Price Index Methodology
The hedonic pricing approach has a long tradition in economic measurement, going back almost a century. 19 In essence, the hedonic approach treats the item being priced as a bundle of observed characteristics, and using multivariate regression methods, estimates "shadow prices"
of each of the observed characteristics and the aggregate price index as a composite of the observed characteristics each multiplied by its shadow price. In practice, given observations in each period t on the prices P it of a set of items i with characteristics X it , this means estimating a regression model on pooled data of the form log(P it ) = X it β+γZ t +ε it where Z t is a set of dummy variables for each period and ε it is a random error term. This semi-log functional form is widely used in hedonic price analysis. 20 Predicted values from this regression provide the basis for computing changes in a "quality-adjusted" composite price index P t : with a set of time dummies in the regression, the change in the composite index relative to the base period is given by the exponentiated values of their estimated coefficients ( �). Although E[exp(P)] ≠ exp(E[P]) and ε it may not be homoscedastic, suggesting a "smearing" adjustment of the type discussed in the medical costs literature, 21 with time dummies in the regression these adjustment factors will typically be small. 22 In this application, the "priced item" is the investigator total grant cost per patient. TGPP, and our hedonic regression takes the form log(TGPP it ) = X it β+γZ t +ε it , with X containing site and trial characteristics including planned number of patients at the investigator's site, location and number of sites and countries participating in the trial, phase of development, therapeutic area, and the site work effort (SWE) measure of trial burden and complexity.
(In the case where residuals are homoscedastic within time periods, adjustments such as the nonparametric method proposed by Duan [1983] will give estimates that are numerically identical to non-adjusted ones. We found very similar adjusted and unadjusted estimated index values, and here we report only estimates with no adjustment for cross-year heteroscedasticity.) 23 Z t are annual indicator variables. Estimated standard errors are Huber-White robust, clustered by trial protocol;
computations were carried out in STATA.
IV. Estimation and Price Index Results
We now report results based on various regressions, and calculate corresponding average 24 In all cases the dependent variable is the logarithm of total grant cost per patient (ln TGPP).
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Of particular interest to us are the coefficient estimates on two clinical trial characteristics variables-the logarithm of number patients at the site (lpatients) and site work effort (SWE). Table II ), a one-unit increase in SWE changes it by about 4% (1/25), leading to about on average a 2% increase in TGPP, suggesting an elasticity of TGPP with respect to SWE at about 0.50 (= 0.02/0.04). That is a very substantial effect.
A third implication of findings in Table VI is that they help explain factors affecting increases in trial costs. Specifically, as SWE has increased over time and number of patients has decreased, particularly in the US where for each phase coefficients on lpatients are mostly negative, TGPP is increased. Whether the changing composition among trial phases (towards Phase II and away from Phase IIIA-see Table III ) can "explain" the increase in TGPP merits further examination.
We now move on to consider implications of these various regression models for the growth rate of our price indexes. As discussed above, annual values of an hedonic price index can be constructed from estimated coefficients on indicator variables for year. We summarize the growth rate of this index by computing the Annual Average Growth Rate (AAGR), which is the mean of year-on-year percentage changes in the index values. 27 The bottom three panels of In the top panel of Table VII we report estimates of AAGRs in a "base" model that excludes our two prominent quality measures, namely, lpatients and SWE, which from AAGRs, and helps explain in part why it is that TGPP has been increasing steadily over the last two decades.
as seen in the second and third column there is considerable variation across the two time intervals within the pooled regression. We conclude that constructing price indexes for clinical trials at the level of therapeutic classes (in our case, which number 15) is likely to be infeasible because of sample size issues, particularly for ex-US sites.
Our final exploratory price index analysis involves aggregating up from individual multiple sites within a given trial to the trial level at which there is a common protocol. This allows us to examine whether number of trial sites and the geographical scope of the sites affects our dependent variable, ln TGPP. This aggregation reduces our sample size from the 207,950 sites in Table VI We do not have a prior expectation regarding the sign of the coefficient on total number of sites per trial. This coefficient will capture whether or not there are cost impacts (at the site level) of allocating a given number of patients across different numbers of sites. To the extent there are fixed costs incurred at each site for setting up patient recruitment, independent of the number of patients enrolled at a given site, then holding the numbers of patients constant the aggregate TGPP would be expected to increase with the number of sites. On the other hand, if fixed costs are largely trial specific rather than site-specific, and are carried in the "overhead" part of trial costs which we do not observe in these data, then they will either not affect site-level costs, i.e.
no observable impact of number of sites on aggregate TGPP, or to the extent that they reduce site-specific costs otherwise borne by investigators, will result in a negative relationship between aggregate TGPP and number of sites. Some of these trial-level fixed costs are likely to be country-specific, reflecting factors such as national institutional review boards, import duties and tariffs, medical licensing conventions or other costs of conforming to a given country's regulatory framework and infrastructure. To the extent that these costs are "pushed down" to individual sites, rather than absorbed in the overall "overhead" cost of the trial then aggregate TGPP may be affected by the number of sites per country. We therefore also control for each trial's number of sites per country.
In Table IX , we report coefficient estimates on the number of sites, and the number of sites per country, for regressions at two levels of aggregation: Pooled over phases (but with phase indicator variables included as regressors), and separately by trial phase. 28 When pooled over phases, the estimate on number of sites is positive and strongly significant, while the number of sites per country is negative but not significant. When estimated separately by phase, signs on the number of sites variable are mixed but monotonically decline moving from early to late phases, and although none is statistically significant. However, all but one of the estimates on the number of sites per country are positive, statistically significant in the case of Phase II and IIIA trials. In almost all cases, however, the absolute magnitudes of the coefficient estimates are very small-an order of magnitude or smaller than those on the lpatient and SWE variables reported in Table VI . We conclude that at the level of a clinical trial protocol, the number of sites and number of countries per site do not appear to have a material effect on the total grant cost per patient. These trial characteristics might, however, have varying effects on the sponsors' overall "headquarters" overhead costs, which we do not observe.
V. Summary, Conclusions, Limitations and Future Research
Expenditures on clinical trials required to develop new drugs have increased dramatically over the past 30 years. To better understand the underlying causes it is important to be able to decompose increases in total spending into the "price effect", the "quantity effect," and the "quality" effect. Are biopharmaceutical companies doing more clinical research, or has the cost of doing a given amount of research increased, or are both occurring? In this study we focus on the "unit costs" of some aspects of conducting clinical trials. These have risen substantially in recent decades, outpacing general inflation and other measures of changes in costs of other inputs to biomedical R&D. Our results suggest that these increases in trial costs are not solely attributable to changes in input costs such as wages, equipment, and facilities. They also appear to have been driven to a substantial extent by two other phenomena: smaller numbers of patients per site, and increases in the "effort" level required by investigators as study protocols have required more costly and complex monitoring and testing of subjects. While these in turn are driven to some extent by cost differences across therapeutic classes and phases of clinical development, the effects we find are estimated controlling for such study characteristics, and are not just an artifact of changes in the composition of the sample. The size of the effects that we find implies that any effort to track costs of clinical research should pay close attention to the nature of study protocols and the organization and management of trials. These findings point to the value of using the hedonic regression methodology in this context.
The price indexes for commercial clinical research constructed here appear to behave very differently from those computed by NIH for input costs for public sector biomedical R&D, and may merit more careful attention by government statistical agencies and other entities with an interest in tracking R&D costs in this sector. The AAGR of a price index that controls for therapeutic class and phase of development grows almost twice as fast as the NIH BRDPI input costs index. Interestingly, once the scale of investigator/site activity and the effort required by a study protocol are also controlled for, the estimated "quality-adjusted" rate of inflation within the US is quite similar to the BRDPI. This suggests that increases in commercial clinical trial costs are driven primarily by changes in the nature of clinical research rather than by inflation in input costs. Commercial databases such as the one we have used here appear to have great potential as a source of data for such price index measurement purposes. Using these data it would appear to be feasible to reliably compute measures of price inflation for this aspect of clinical research, and to do this separately for different phases of clinical development, and for some but not all therapeutic classes. The geographic reach of these data sources also presents interesting opportunities to benchmark R&D costs across different regions and countries.
There are some important limitations to our study. In particular, we look only at one component of trial costs: payments to clinical investigators. In this dataset, these account for about one half of the total cost of a trial. It may well be that some of the higher per-patient costs created by having fewer patients per site and increased effort required by the protocol are offset by savings in the costs of centralized administration and co-ordination of trials that we do not observe here. Limited availability of data prevents us from drawing strong conclusions about trends in total trial costs and underlying factors in recent years. Further, it is unclear how well the measure of "site work effort" used here captures differences in the burden imposed by, for example, running more complex trial protocols, as opposed to use of more costly interventions or methods of measuring endpoints. Lastly, since the identity of study sponsors and investigators was not available to us, we were not able to investigate differences in costs across (for example) trials sponsored by large versus small commercial entities, or where public sector or non-profit organizations are involved as sponsors or investigators.
We look forward to addressing these questions in future work. 
